Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study investigated the immune response induced by the Group B streptococcus vaccine in healthy pregnant women. In addition, the study investigated the amount of vaccine induced antibodies which were transferred to the newborn.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings

NCT01412801

Streptococcal Infections Gram-Positive Bacterial Infections Bacterial Infections

COMPLETED PHASE2

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age

NCT01193920

Streptococcal Infections

COMPLETED PHASE1/PHASE2

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

NCT06592586

Streptococcus Agalactiae Infection Neonatal Sepsis Pneumonia +6 more

RECRUITING PHASE2/PHASE3

Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial

NCT02528981

Group B Streptococcal Infection

COMPLETED NA

Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease

NCT04735419

Streptococcus Agalactiae Infection

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Streptococcal Infection Gram-positive Bacterial Infection Bacterial Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group B Streptococcus Trivalent Vaccine

Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine.

Group Type EXPERIMENTAL

Group B Streptococcus Trivalent Vaccine

Intervention Type BIOLOGICAL

Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.

Placebo

Pregnant women who received one injection of saline solution.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Pregnant women who received one injection of saline solution administered intramuscularly.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group B Streptococcus Trivalent Vaccine

Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.

Intervention Type BIOLOGICAL

Placebo

Pregnant women who received one injection of saline solution administered intramuscularly.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy pregnant women 18-40 years of age at 24-35 weeks of gestation at screening.
2. Individuals who have given a written consent after the nature of the study has been explained according to local regulatory requirements.
3. Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
4. Individuals who will be available for all scheduled visits (ie, not planning to leave the area before the end of the study period).

Exclusion Criteria

1. Individuals who were unwilling and/or unable to give written informed consent to participate in the study.
2. Individuals with a history of severe allergic reactions after previous vaccinations such as anaphylactic shock, asthma, urticaria, or other allergic reaction or hypersensitivity to any vaccine component.
3. Individuals with any known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from:

* receipt of immunosuppressive therapy within 30 days prior to enrollment (any systemic corticosteroid administered for more than 5 days, or in a daily dose \> 15 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy).
* receipt of immunostimulants.
* receipt of parenteral immunoglobulin preparation, blood products, and /or plasma derivatives within 12 weeks prior to enrollment and for the full length of the study.

Note: Anti-D (Rho) Immunoglobulins (anti-RhD) given for Anti-D prophylaxis were to be allowed.
4. Individuals characterized as "high risk" pregnancies at investigator discretion, such as those who have:

* gestational diabetes
* preeclampsia/eclampsia
* women at risk of preterm labor (except positivity for vaginal GBS)
* History of previous pregnancy complications including delivery of preterm infant.
* History of still-birth, late abortions and children with congenital anomalies.
5. Individuals who had received any other investigational agent or investigational intervention during the course of the study.
6. Individuals with acute infection including oral temperature ≥ 38°C were to be temporarily excluded. They could be enrolled once the infection had resolved (as judged by investigator).
7. HIV positive by history.
8. Individuals reporting any known or suspected serious acute, chronic or progressive disease (eg, any history of neoplasm, malignancy, including lymphoproliferative disorder, diabetes, cardiac disease, malnutrition, renal failure, autoimmune disease, HBV or HCV, blood disorders).

Note: Malignancies, highly likely to having been cured at the investigators discretion are allowed. (eg, no relapse since 5 years post last malignancy specific treatment).
9. Individuals with bleeding diathesis, or any condition that might have been associated with a prolonged bleeding time.
10. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, might have interfered with the subject's ability to participate in the study (eg, who were not able to comprehend or to follow all required study procedures for the whole period of the study).
11. Individuals with any progressive or severe neurologic disorder, seizure disorder, epilepsy or Guillain-Barré syndrome.
12. Individuals with history or any illness that, in the opinion of the investigator, might have posed additional risk to subjects due to participation in the study.
13. Individuals who were part of study personnel or close family members conducting this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes